India-based pharmaceutical giant to manufacture up to 200 million doses of Russia's Covid-19 vaccine, Sputnik V.
The Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund, said in a statement that it has partnered with the Virchow Group to produce up to 200 million doses of the two-dose vaccine in India every year.
Following the partnership agreement, Virchow Biotech, a subsidiary of the Virchow Group, is expected to start full-scale commercial production in the first half of 2021.
RDIF CEO Kirill Dmitriev said the agreement was “an important step to facilitate the full-scale local production” of the two-dose Sputnik V vaccine in India and to supply partners around the world.
In addition to this, RDIF has also secured production agreements with two other Indian manufacturers; Stelis Biopharma and Gland Pharma.
The companies are expected to produce enough doses for 300 million people a year.
According to RDIF, Russia’s Covid-19 vaccine, Sputnik V - which is named after the Soviet-era satellite, has been registered in 54 countries.
The Russian Direct Investment Fund (RDIF), the country’s sovereign wealth fund, said in a statement that it has partnered with the Virchow Group to produce up to 200 million doses of the two-dose vaccine in India every year.
Following the partnership agreement, Virchow Biotech, a subsidiary of the Virchow Group, is expected to start full-scale commercial production in the first half of 2021.
RDIF CEO Kirill Dmitriev said the agreement was “an important step to facilitate the full-scale local production” of the two-dose Sputnik V vaccine in India and to supply partners around the world.
In addition to this, RDIF has also secured production agreements with two other Indian manufacturers; Stelis Biopharma and Gland Pharma.
The companies are expected to produce enough doses for 300 million people a year.
According to RDIF, Russia’s Covid-19 vaccine, Sputnik V - which is named after the Soviet-era satellite, has been registered in 54 countries.
